New Risk • Jun 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (191% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.09m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$8.9m net loss in 3 years). Announcement • Jun 09
Galmed Pharmaceuticals Ltd. (NasdaqCM:GLMD) agreed to acquire Cologuard for $4.5 million. Galmed Pharmaceuticals Ltd. (NasdaqCM:GLMD) agreed to acquire Cologuard for $4.5 million from shareholders of Colospan and Boaz Assaf on June 8, 2026. Under the terms of the definitive agreement, Colospan shareholders and SAFE holders will receive $2.5 million in cash to Selling Shareholders and certain SAFE investors and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow. Upon closing, Colospan will become a wholly owned subsidiary of Galmed, repositioning it as a GI-focused medtech and biopharmaceutical platform.
The transaction is subject to approval of merger agreement by target board and approval of offer by acquirer board. The deal has been unanimously approved by the board. The transaction is subject to customary closing conditions and is expected to close in Q2 2026.
ROTH Capital Partners, LLC acted as financial advisor and Meitar Liquornik Geva Leshem Tal & Co acted as legal advisor for Galmed Pharmaceuticals Ltd. Matri Meiri Wacht & Co acted as legal advisor for Cologuard. Announcement • Jun 02
Tissue Dynamics and Galmed Pharmaceuticals Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure and Support the Development of Aramchol for Cardiac Fibrosis Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models. In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARa agonist reduced fibrotic burden by approximately 4-fold. Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. announced results from a preclinical study evaluating a combination of Aramchol Meglumine, an SCD1 inhibitor, and a selective PPARa agonist. The study identified a previously unrecognized metabolic pathway involved in the progression of cardiac fibrosis and heart failure and demonstrated that the two-drug combination effectively targets this mechanism. Progressive cardiac fibrosis, driven by ischemic injury or age-related metabolic dysfunction, results in pathological scarring of the heart muscle, leading to tissue stiffening and impaired systolic and diastolic function. Cardiac fibrosis is a major contributor to heart failure progression and remains an area of significant unmet medical need. Despite advances in cardiovascular care, no therapies directly reverse established cardiac fibrosis, highlighting the need for novel therapeutic approaches. One of the major challenges in cardiac drug development is the substantial physiological and metabolic differences between rodent and human hearts. As a result, findings from animal models often fail to translate successfully into human clinical outcomes. Using its robotic DynamiX platform and advanced human cardiac organoid models, Tissue Dynamics identified a novel human-specific metabolic mechanism that would not have been readily detectable using conventional animal models. The study demonstrated that a combination of Aramchol Meglumine and a selective PPARa agonist modulates two key pathological processes—mitochondrial stress and associated lipogenesis—that contribute to the development and progression of cardiac fibrosis and heart failure. Leveraging Tissue Dynamics' machine-learning platform, researchers identified and validated a previously unknown metabolic pathway underlying the synergistic effects of the combination therapy. In inflammatory human cardiac organoids, the treatment reduced fibrotic burden by approximately fourfold. 
